RAPT Therapeutics (NASDAQ:RAPT) reported quarterly losses of $(0.63) per share. This is unchanged from the same period last year.
Repo Rates Spike: Are Lessons Of The 2019 Funding Crisis Being Heeded?
The U.S. repo market is experiencing stress due to rising short-term interest rates, reminiscent of the 2019 funding crisis.